Drug Discovery World

JUNE 7, 2024

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event.

Vaccine 130

Vaccine Drugs Trials Research 130

Drug Discovery World

APRIL 19, 2024

Human infection model drives forward TB vaccine development For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The post This week in drug discovery (15-19 April) appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Vaccine Trials Drugs 130

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Discovery World

SEPTEMBER 4, 2023

SLAS2024 event partner DDW will be the exclusive sponsor for the SLAS Ignite Theater, hosting its own free to attend seminar series, ‘Innovation & technology: from lab to patient’. How using technology to identify previously undruggable targets has enabled the development of therapeutics and vaccines.

Vaccine 130

Vaccine Science Pharmaceuticals Disease 130

Drug Discovery World

MAY 11, 2023

DDW’s Megan Thomas spoke with attendees, and comments on the event. Fundraising and investment Coming out of a global pandemic, in-person events initially added a degree of novelty to networking. At previous events, there has been an air of excitement but uncertainty of how quickly to adopt ‘business as usual’.

Targeted Protein Degradation 130

Targeted Protein Degradation Science Small Molecule Vaccine 130

Drug Discovery World

FEBRUARY 24, 2023

Our news highlights this week focus on research into vaccines, with good news for the treatment or prevention of various challenging conditions, including Covid-19, Strep A and HIV. Particularly interesting is the announcement that a new class of Covid-19 booster has outperformed approved vaccines in a head-to-head trial.

Vaccine 130

Vaccine Drugs Clinical Trials Virus 130

Drug Discovery World

JANUARY 31, 2024

By Megan Thomas, DDW Multimedia Editor The last time the DDW team were in Boston for a SLAS event two years ago, the world was very much in the early recovery period of Covid-19. For many, it was their first in-person event – a welcome return.

Government 130

Government Vaccine Disease Science 130

Drug Discovery World

FEBRUARY 15, 2024

The etherna paradigm for cLNP design is ushering in the rapid generation of novel families of delivery systems for not only vaccination but also for in vivo tolerisation for a host of autoimmune diseases.” The post LNP formulations produce strong immune responses, data shows appeared first on Drug Discovery World (DDW).

Immune Response 130

Immune Response Vaccine RNA Pharmaceutical Companies 130

Drug Discovery World

JULY 8, 2022

GSK’s annual Palio meeting is taking place with a focus on how preventative approaches to disease can help mitigate climate change. . GSK’s ‘Vaccines for a sustainable planet’ meeting is gathering 65 experts across immunology, vaccinology, epidemiology, and policy throughout 7-8 July. . Official comments ? .

Vaccine 130

Vaccine Disease International 130

Drug Discovery World

JANUARY 21, 2024

Inspired by the overall event theme of ‘Innovation at Every Turn’, the DDW track will present leading research and case studies from experts in academia, government agencies and the industry on how technology is innovating from bench to bedside, lab to patient.

Vaccine 130

Vaccine Computational Chemistry Animal Testing Engineering 130

Drug Discovery World

SEPTEMBER 14, 2023

Total revenue from oncology medicines increased 22%, CVRM 20%, R&I8 10%, and rare disease 12%. Vaccines were up 9.1% Moreover, in July 2023, AstraZeneca and Vaxess Technologies commenced a collaboration for the evaluation of a novel RNA-based pandemic influenza prototype vaccine in patch format. Specialty care grew 11.8%

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

Drug Discovery World

FEBRUARY 29, 2024

CureLab Oncology’s DNA vaccine Elenagen, in combination with chemotherapy, has demonstrated promising clinical results against triple-negative ovarian cancer. There were no serious adverse events (SAEs) reported in patients receiving Elenagen. Gemcitabine alone had an average PFS similar to previously reported durations: 2.7

DNA 130

DNA Drug Development Vaccine International 130

Drug Discovery World

DECEMBER 13, 2023

The event will take place on 5 and 6 February 2024 at SLAS in Boston, and will present leading research from experts in academia, government agencies and industry on how technology is innovating from bench to bedside, lab to patient.

Engineering 130

Engineering Government Vaccine Science 130

Drug Discovery World

MAY 25, 2023

The event brought together organisations representing different aspects of drug discovery, including research institutes, academia and industry, emphasising the importance of partnership and collaboration in this dynamic sector.

Research 130

Research Virus Drugs Disease 130

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

JUNE 24, 2021

The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines. Secondary objectives are to describe immune responses produced by each of the vaccines.

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

JANUARY 25, 2021

Anaphylaxis Cases Reported Per Million COVID-19 Moderna Vaccine Shots. cases per million Moderna COVID-19 vaccine doses administered as of Jan. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. anaphylaxis cases per million Moderna COVID-19 vaccine doses administered). Professional.

Vaccine 52

Vaccine Research Disease 52

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Why are challenge trials becoming more popular?

Vaccine 132

Vaccine Trials Disease Virus 132

The Pharma Data

JUNE 7, 2023

This is the first time an RSV vaccine for older adults has been granted European Marketing Authorisation. This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation. The vaccine was generally well tolerated.

Virus 40

Virus Vaccine Disease Trials 40

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 1 TICOVAC is the only FDA-approved vaccine to help protect U.S. We are proud to deliver the first vaccine to help protect people in the U.S. 45 years ago.

FDA Approval 52

FDA Approval Vaccine FDA Virus 52

The Pharma Data

JANUARY 7, 2021

Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported. per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Vaccine 52

Vaccine Research Disease Drugs 52

The Pharma Data

JULY 23, 2021

government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. government with 500 million doses of the companies’ COVID-19 vaccine for donation to the world’s poorest nations. government in the fight against this pandemic, we are proud of the impact of vaccination efforts across the country.

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

SEPTEMBER 5, 2021

AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the Advance Purchase Agreement for the delivery of the COVID-19 vaccine Vaxzevria (ChAdOx1-S [Recombinant]). To date, AstraZeneca and its partners have supplied more than 1.1 Vaxzevria (ChAdOx1-S [Recombinant]).

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

SEPTEMBER 5, 2021

million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines. The work is supported by the Centers for Disease Control and Prevention (CDC). “The world is relying on safe and effective vaccines to bring an end to the COVID-19 pandemic. . The total number of people evaluated was 6.2

Vaccine 52

Vaccine Clinical Trials Research Virus 52

Drug Discovery World

JANUARY 22, 2024

At this year’s SLAS event, DDW has curated a track taking place in the Ignite Theater. Masaru Kanekiyo , Chief of Molecular Immunoengineering Section (MIS) of the Vaccine Research Center (VRC) at the US National Institute of Allergy and Infectious Diseases (NIAID), will present ‘Structural vaccinology for influenza’.

Immune Response 147

Immune Response Vaccine Engineering Virus 147

The Pharma Data

DECEMBER 14, 2020

14, 2020 — The Pfizer-BioNTech COVID-19 vaccine has received the first emergency use authorization (EUA) for a COVID-19 vaccine in the United States. Centers for Disease Control and Prevention Director Robert R. The vaccine is administered in two doses three weeks apart. MONDAY, Dec. Redfield, M.D.,

Vaccine 52

Vaccine Nurses FDA Virus 52

The Pharma Data

JANUARY 8, 2021

Moderna COVID-19 Vaccine Protection May Last Years, Company Claims. 8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday. Professional. FRIDAY, Jan. Natural immunity varies from person to person, CBS News reported. CBS News Article.

Vaccine 52

Vaccine Virus Disease 52

The Pharma Data

JANUARY 21, 2021

21, 2021 — Despite scattered media reports of severe allergic reactions to the Pfizer COVID-19 vaccine, a detailed analysis shows that such incidents are very rare, striking just 11 people for every million doses given. Tom Shimabukuro tracked data on reactions to the Pfizer vaccine soon after it was approved in December.

Vaccine 52

Vaccine Hospitals Disease Research 52

The Pharma Data

JANUARY 29, 2021

29, 2021 — Interim phase 3 data show that the COVID-19 vaccine developed by Janssen Pharmaceuticals of Johnson & Johnson is 66 percent effective in preventing moderate-to-severe COVID-19 in adults, the National Institutes of Health announced today. The vaccine, known as Ad.26.COV2.S, The vaccine, known as Ad.26.COV2.S,

Vaccine 52

Vaccine Clinical Trials Trials Disease 52

Drug Discovery World

AUGUST 30, 2022

Recently, the Centers for Disease Control and Prevention (CDC) allowed physicians to prescribe tecovirimat on a compassionate use basis to treat adults and children with orthopoxvirus infections, including monkeypox. The researchers have called for large-scale studies to explore antiviral efficacy dosing and adverse events.

Therapies 130

Therapies FDA Approval Vaccine Treatment 130

The Pharma Data

JULY 15, 2021

FreVAX is an innovative intramuscular needle free vaccine injection device for pigs around weaning until the end of nursery. to provide improved vaccination compliance and data management,” added Marius Leyhausen, Senior Global Brand Manager, Integrated Health Management at Boehringer Ingelheim Animal Health. The FreVAX app 2.0

Vaccine 52

Vaccine Compliance Disease 52

The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

JUNE 24, 2021

This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group. COMIRNATY was the first COVID-19 vaccine to receive authorization in the EU and is the first to have its CMA extended to adolescents. g doses of the COVID-19 vaccine.

Vaccine 52

Vaccine Clinical Trials FDA Trials 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. A recent COVID-19 infection could put a person a bit farther back in line for the vaccine, however. FRIDAY, Dec.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. .–( BUSINESS WIRE )– Moderna, Inc.,

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

MAY 5, 2022

The Fact Sheet for Healthcare Providers Administering Vaccine now reflects the revision of the authorized use of the Janssen COVID-19 Vaccine and includes a warning statement at the beginning of the fact sheet for prominence which summarizes information on the risk for TTS.

Vaccine 52

Vaccine FDA Pharmaceutical Companies Production 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 — A second COVID-19 vaccine is poised to be administered in the coming weeks after the U.S. Food and Drug Administration granted emergency use authorization (EUA) to the Moderna COVID-19 vaccine on Friday. The EUA allows for the vaccine to be administered to adults 18 years and older in two doses one month apart.

Vaccine 52

Vaccine FDA Hospitals Disease 52